Logo

Innovent Entered into a Collaboration Agreement with NeoCura to Evaluate Sintilimab + NEO_PLIN2101 for Cancer in China

Share this

Innovent Entered into a Collaboration Agreement with NeoCura to Evaluate Sintilimab + NEO_PLIN2101 for Cancer in China

Shots:

  • The companies collaborated to evaluate the safety, PK, PD & preliminary efficacy of the combination therapy of Innovent’s sintilimab + NeoCura’s NEO_PLIN2101 in patients with cancer
  • The collaboration will bolster the clinical development of combination immunotherapy for multiple solid tumors & the companies plan to submit an IND application to the NMPA imminently
  • Innovent is currently conducting 20+ clinical studies of sintilimab to assess safety and efficacy for multiple cancer indications including 10+ registrational or pivotal clinical trials. Additionally, sintilimab is currently under review in China & has one regulatory submission for the 1L treatment of ESCC

 ­ | Ref: PR Newswire | Image: Innovent

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions